An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab in pediatric participants with mild to moderate COVID-19 at high risk of disease progression (COMET-PACE) (215226)

03/05/2022
29/05/2024
EU PAS number:
EUPAS47006
Study
Finalised
Documents
Study protocol
Study results
Study report
Other information